Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy

BACKGROUND: The newly synthesized Aurora-A kinase inhibitor XY-4 is a potential anti-cancer agent, but its hydrophobicity and limited efficiency restrict further application. Nanotechnology based combined therapy provides an optimized strategy for solving these issues. METHODS: In this study, the ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Xingmei, Mu, Minjie, Yan, Junfeng, Bai, Lan, Zhong, Lei, Zhu, Yuxuan, Pan, Haixia, Zhang, Mei, Shi, Jianyou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849942/
https://www.ncbi.nlm.nih.gov/pubmed/29563798
http://dx.doi.org/10.2147/IJN.S147759

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849942/
https://www.ncbi.nlm.nih.gov/pubmed/29563798
http://dx.doi.org/10.2147/IJN.S147759

Ejemplares similares